Indapta Therapeutics Inc. — Form D
Indapta Therapeutics Inc. of Houston, TX, a company, filed a Form D exempt-offering notice with the SEC on 2022-02-10. The offering totals $67.1M, of which $33.6M was reported sold. Industry: Other Technology.
Offering
- Filed: 2022-02-10
- Form: D
- Accession: 0001910175-22-000001
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $67.1M
- Amount sold: $33.6M
- Remaining: $33.5M
- Investors: 37
- Date of first sale: 2022-01-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-433098
Issuer
- Name: Indapta Therapeutics Inc.
- CIK: 0001910175
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 5000 Gulf Fwy. Building 4, Houston, TX, 77023
- Phone: 917-282-9768
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Laura Stoppel | Director | Sacramento, CA |
| Guy DiPierro | Executive Officer | Houston, TX |
| Lori Hu | Director | Houston, TX |
| Fabio Pucci | Director | Houston, TX |
| Ronald Martell | Director | Houston, TX |
| Mark Frohlich | Director | Houston, TX |
| Mark Frohlich | Executive Officer | Houston, TX |
Other filings by this issuer (1)
More